Femasys Inc.
FEMYNASDAQHealthcareMedical - Instruments & Supplies
Latest quote
$2.97
+$0.23 · +8.42%
FEMY company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
66
Undervalued
Momentum
17
Strong Down
Sentiment
49
Mixed
Risk resilience
34
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteFemasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Kathy Lee-Sepsick
- Listed since
- Jun 18, 2021
- Employees
- 53
Market position
- Volume
- 584.93K
- 6.77× average
- Average volume
- 86.45K
- Average daily volume
- Market cap
- 8.94M USD
- Beta
- -2.09
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 18.21M USD
- P/E (TTM)
- -0.65×
- P/B (TTM)
- 2.47×
- P/S (TTM)
- 3.89×
- EV / EBITDA
- -1.15×
- Earnings yield
- -81.77%
- Free cash flow yield
- -84.35%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 52.16%
- Operating margin
- -763.90%
- Net margin
- -534.27%
- Return on equity
- -317.38%
- Return on assets
- -89.88%
- Return on invested capital
- -100.07%
Financial health
- Debt / equity
- 1.19×
- Current ratio
- 4.53×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.29M USD | 1.63M USD | 1.07M USD | 1.21M USD | 1.18M USD |
| Cost of goods sold | 872.4K USD | 544.9K USD | 380.07K USD | 441.94K USD | 370.38K USD |
| Gross profit | 1.42M USD | 1.08M USD | 691.9K USD | 764.28K USD | 809.31K USD |
| Research and development | 7.58M USD | 8.22M USD | 7.21M USD | 5.81M USD | 4.08M USD |
| Selling, general, and administrative | 11.09M USD | 10.36M USD | 7.51M USD | 5.99M USD | 4.47M USD |
| Operating expenses | 19.01M USD | 18.87M USD | 15.2M USD | 12.36M USD | 9.15M USD |
| Interest income | 101.76K USD | 582.35K USD | 431.02K USD | 228.16K USD | 3.77K USD |
| Interest expense | 1.89M USD | 1.6M USD | 165.39K USD | 13.46K USD | 19.23K USD |
| Depreciation and amortization | 850.46K USD | 872K USD | 907.99K USD | 889.14K USD | 964.29K USD |
| Operating income | −17.59M USD | −17.79M USD | −14.51M USD | −11.6M USD | −8.34M USD |
| Net income | −18.63M USD | −18.82M USD | −14.25M USD | −11.39M USD | −7.54M USD |
Company facts updated Aug 24, 2026.
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 8, 2026 | 1:20 | — | — |
Effective Jun 8, 2026
1:20
FEMY peers
Continue in GoAI
Research FEMYresearch.disclaimer